Treatment with anti-IL-17A antibody efficiently eradicated cutaneous lesions and decreased peripheral oxidative stress in two (CD11c-IL-17Aind/ind mice and mice with imiquimod induced psoriasis) assessed the models of psoriasis. This evidence concerns the gene IL17A and psoriasis.